Issue No. 8 · Week of October 5, 2026
The biggest operational item this week is the FDA registration and listing window that opened October 1, alongside Health Canada’s November 1 licence renewal deadline, so both North American filings need to start now. Longer FDA review times, CMS ending automatic extra payment for new breakthrough devices and a still open Section 232 device probe all point toward higher cost and slower timelines for foreign manufacturers. Hospital consolidation keeps resetting purchasing contracts, so confirm where your products now sit.
Hospitals and Health Systems
Hospital deals close as the fourth quarter begins: UPMC enters Ohio and WVU Health reaches 30 hospitals
UPMC completed its purchase of Trinity Health System in Ohio, WVU Health added five Independence Health hospitals, and MaineHealth, Parkview and Tampa General also closed deals. A change of ownership usually moves purchasing onto the new parent’s GPO and contracts, so suppliers should confirm which agreements and credentialing now apply.
Source: Becker’s Hospital Review
Vizient previews supply chain tools that weigh cost, utilization and outcomes, launching in early 2027
The tools include contract price assurance and a clinically integrated sourcing tool meant to steer member spend toward on contract products and flag price discrepancies. Manufacturers without a Vizient contract, or whose pricing drifts from contract terms, are more likely to be flagged and displaced.
Source: Vizient via Business Wire
Federal Health Systems: VA and DoD
VA inspector general flags weak price protections in Federal Supply Schedule contracts
The memo says VA guidance on tracking customers is outdated and not consistently shared with vendors, and that resellers without significant commercial sales are not required to submit manufacturer disclosures. A foreign manufacturer selling to VA through a U.S. distributor should expect tighter pricing disclosure requests and keep commercial pricing records consistent with its FSS offer.
Source: VA Office of Inspector General
Regulatory: FDA and Health Canada
FDA annual registration and device listing window opens for FY2027
Foreign establishments must renew registration and update device listings, U.S. Agent and importer details between October 1 and December 31, 2026. Missing this can affect lawful importation into the U.S., so start the renewal now and confirm the fee against FDA’s FY2027 notice.
Source: Complife Group
Health Canada licence renewal deadline is November 1 for Class II, III and IV devices
Licence holders must confirm their information is accurate or submit amendments before November 1, 2026. A missed renewal can put a licence at risk and stop sales into Canadian hospitals, so check that your renewal package was received and complete.
Source: Complife Group
CDRH publishes its FY2027 guidance agenda, led by AI lifecycle, PCCPs, robotic surgery and QMS content
CDRH plans 11 final and 3 draft guidances, with comments open until November 30, 2026 under Docket FDA-2012-N-1021. Final guidance will set what FDA expects in 510(k) and PMA files, so check whether your submissions touch these topics and consider commenting.
Source: RAPS
CMS ends automatic extra Medicare payment pathways for new FDA breakthrough devices
Newly designated breakthrough devices no longer get New Technology Add-on Payment or transitional pass-through eligibility without showing substantial clinical improvement. A foreign manufacturer counting on designation to speed reimbursement now needs clinical evidence, which raises the cost and timeline of a U.S. launch.
Source: STAT
Import, Customs and Trade
Section 232 investigation of medical devices stays open while pharma tariff procedures advance
Commerce has not announced an outcome on devices, even as pharmaceutical tariffs and exemption procedures move forward. A device tariff could still be proclaimed on short notice, so keep landed cost scenarios and country of origin documentation current.
Source: Federal Register; BIS
Court of International Trade hears challenge to Section 301 tariffs covering 99.4 percent of U.S. imports
A three judge panel heard arguments from small businesses and 25 states that the duties exceed presidential authority. No ruling has been reported, but a decision could change duty rates on imported devices and open refund questions for importers of record, so keep entry records in order.
Source: CNBC
Also Noted
Draeger neonatal breathing circuit hoses classified as Class I recall
Draeger VentStar Resus Neo neonatal breathing circuit hoses classified Class I recall; expect hospital questions on material integrity for single-use tubing.
Source: FDA
Health Canada consultation on recognized standards closes
Health Canada consultation on the List of Recognized Standards closed September 25; check that standards cited in your licence files stay on the revised list.
Source: Quality Smart Solutions
Key Takeaways for Medical Device Manufacturers
This week’s developments highlight several immediate compliance and market access priorities. Foreign manufacturers should complete FDA establishment registration and device listing updates during the October 1 through December 31 renewal window, while Canadian Class II, III and IV device licence holders should address the November 1 renewal deadline.
Manufacturers should also account for changing Medicare reimbursement requirements, potential Section 232 device tariffs and evolving FDA guidance expectations. With hospital acquisitions and new purchasing tools reshaping supplier relationships, it is important to confirm current GPO contracts, pricing arrangements and vendor credentialing requirements.
Questions About U.S. or Canadian Market Access?
Dawa Medical supports foreign medical device manufacturers entering the U.S. market as U.S. Agent, FDA Initial Importer and Importer of Record, with 3PL warehousing and regulatory compliance support. Through TB Medical Inc., manufacturers can also access Canadian importation and distribution support.
About The Access Brief: The Access Brief summarizes publicly reported news affecting medical device manufacturers selling into the United States and Canada and reflects Dawa Medical’s own understanding. It is not legal, regulatory or binding advice, and formal advice should come from qualified counsel or a specialist consultant.
